- Home
- BVFL vs ATYR Comparison
BVFL vs ATYR Comparison
Compare BVFL & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- ATYR
- Stock Information
- Founded
- BVFL 1873
- ATYR 2005
- Country
- BVFL United States
- ATYR United States
- Employees
- BVFL N/A
- ATYR N/A
- Industry
- BVFL Savings Institutions
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BVFL Finance
- ATYR Health Care
- Exchange
- BVFL Nasdaq
- ATYR Nasdaq
- Market Cap
- BVFL 205.3M
- ATYR 228.1M
- IPO Year
- BVFL N/A
- ATYR 2015
- Fundamental
- Price
- BVFL $17.14
- ATYR $3.63
- Analyst Decision
- BVFL
- ATYR Strong Buy
- Analyst Count
- BVFL 0
- ATYR 5
- Target Price
- BVFL N/A
- ATYR $19.25
- AVG Volume (30 Days)
- BVFL 31.0K
- ATYR 960.8K
- Earning Date
- BVFL 01-28-2025
- ATYR 03-13-2025
- Dividend Yield
- BVFL N/A
- ATYR N/A
- EPS Growth
- BVFL N/A
- ATYR N/A
- EPS
- BVFL 1.20
- ATYR N/A
- Revenue
- BVFL $38,028,000.00
- ATYR $235,000.00
- Revenue This Year
- BVFL N/A
- ATYR N/A
- Revenue Next Year
- BVFL N/A
- ATYR $1,080.92
- P/E Ratio
- BVFL $14.33
- ATYR N/A
- Revenue Growth
- BVFL 0.50
- ATYR N/A
- 52 Week Low
- BVFL $10.14
- ATYR $1.42
- 52 Week High
- BVFL $18.19
- ATYR $4.23
- Technical
- Relative Strength Index (RSI)
- BVFL 53.00
- ATYR 53.70
- Support Level
- BVFL $16.54
- ATYR $3.17
- Resistance Level
- BVFL $17.25
- ATYR $3.83
- Average True Range (ATR)
- BVFL 0.31
- ATYR 0.25
- MACD
- BVFL -0.03
- ATYR -0.02
- Stochastic Oscillator
- BVFL 74.40
- ATYR 43.60
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. It offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, business checking as well as certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.